Landmark year: GSK beats quarterly expectations as it plans consumer healthcare spin off April 27, 2022 Healthcare giant GlaxoSmithKline has reiterated its growth outlook after posting first quarter sales of £9.8bn, surpassing analysts’ expectations. The pharmaceutical firm said it anticipated it would deliver sales growth in 2022 of between five to seven per cent at CER and growth of adjusted operating profit of between 12 to 14 per cent at CER. [...]
GlaxoSmithKline clinches cancer specialist Sierra Oncology in $1.9bn deal April 13, 2022 Healthcare giant GSK has snapped up Sierra Oncology, a late-stage biopharmaceutical company focused on rare forms of cancer treatments.
GlaxoSmithKline will not begin any new clinical trials in Russia March 18, 2022 Britain’s second-biggest drug maker, GlaxoSmithKline, won’t begin any new clinical trials in Russia because of the war against Ukraine. It made the announcement following similar moves by major US pharmaceutical giants Pfizer, Merck and Eli Lilly. The UK’s biggest company in the industry, AstraZeneca, is still conducting trials – but is considering ending them, according [...]
GSK looks for covid jab approval as it prepares to spin off consumer arm February 23, 2022 GlaxoSmithKline and French drugmaker Sanofi have announced they are seeking regulatory approvals for their joint covid vaccine as the firms scramble to catch up with competitors after a series of delays.
GlaxoSmithKline revels in £8.8bn profit ahead of consumer healthcare demerger February 9, 2022 GlaxoSmithKline (GSK) has reported full-year sales of £34bn, boosted by strong pharmaceutical sales over the past 12 months.
GSK science chief to depart as pharma giant looks to revamp drugs pipeline January 19, 2022 GlaxoSmithKline's chief scientific officer Hal Barron will leave the firm this year to join a Silicon Valley anti-ageing start up.
Bankers prepare £25bn package as private equity firms circle GSK January 17, 2022 Bankers are putting together major financing packages in preparation of a potential private equity bid for GlaxoSmithKline’s consumer healthcare business.
‘Marmite situation’ for GSK investors as Unilever bids spark potential bidding war January 17, 2022 Analysts have predicted a potential bidding war erupting for GSK’s consumer arm.
Unilever share price dives 7 per cent as £50bn battle for GlaxoSmithKline’s consumer business begins in earnest January 17, 2022 The main City story this morning is the £50bn bid by Unilever for GlaxoSmithKline’s consumer healthcare business, of which it owns a 68 per cent stake along with Pfizer, which Glaxo said it had rejected. “No doubt in the hope that Unilever will come back with a higher offer, with the sum of £60bn being [...]
Healthcare regulator approves GlaxoSmithKline drug for severely ill Covid patients in UK December 2, 2021 A drug treatment which, the makers say, works against the new Omicron variant of Covid-19, has been approved by UK regulators. Xevudy (sotrovimab), made by pharmaceutical giant GlaxoSmithKline (GSK), has been found to cut hospital admission and death by 79% in those at risk. The monoclonal antibody has been authorised by the Medicines and Healthcare [...]